Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 10, No 2 (2017) COSTS OF ANTIRETROVIRAL DRUGS USED IN THE THERAPY OF HIV-INFECTED PATIENTS: A PHARMACOECONOMIC ANALYSIS Abstract  similar documents
M. B. Kubaeva, Y. Sh. Guchshina
"... -sponsored prices and the retail prices of these medications has an impact on the costs of ant-HIV therapy. ..."
 
Vol 11, No 2 (2018) Economic evaluation of postoperative hypofractionated radiation therapy in patients with breast cancer Abstract  similar documents
G. V. Afonin, Yu. A. Ragulin, M. V. Avxentyeva, I. A. Gulidov, S. A. Ivanov, A. D. Kaprin
"... standards, radiation therapy is one of the most important components of the multi-disciplinary treatment ..."
 
Vol 6, No 4 (2013) Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation Abstract  similar documents
A. Yu. Kulikov, L. A. Komarov
"... with standard therapy is characterized as dominant according to cost-effectiveness analysis data. Finally ..."
 
Vol 9, No 2 (2016) PHARMACOECONOMIC ANALYSIS OF THE THERAPY OF СHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS IN HOSPITAL CONDITIONS Abstract  similar documents
E. E. Vidyakina, S. V. Malchikova
"... records of the patient, the analysis of cost of illness, ABC VEN — analysis. Results. The results of АВС ..."
 
Vol 10, No 3 (2017) ABC-analysis of pharmacotherapy in children hospitalized with bronchial asthma exacerbations Abstract  similar documents
O. V. Zhukova, S. V. Kononova
"... . For other drugs, the treatment costs significantly differ between the moderate and severe asthma therapies.  ..."
 
Vol 14, No 1 (2021) Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District Abstract  similar documents
M. S. Soboleva, E. E. Loskutova
"... , Sakhalin Region, Amur Region (n=100) was carried out. The calculation of the monthly cost of therapy ..."
 
Vol 13, No 2 (2020) Affordability of in vivo gene therapy. Problems and potential solutions Abstract  similar documents
V. V. Omelyanovskiy, N. Z. Musina, V. A. Lemeshko, A. A. Antonov, F. V. Gorkavenko
"... Aim. To review foreign approaches to the evaluation and financing of in vivo gene therapy drugs ..."
 
Vol 13, No 2 (2020) Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation Abstract  similar documents
S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova
"... triple therapy of chronic obstructive pulmonary disease (COPD). Materials and Methods. A Markov model ..."
 
Vol 10, No 1 (2017) PERAMPANEL EFFECTIVENESS IN THE TREATMENT OF REFRACTERY PARTIAL ONSET EPILEPSY WITH OR WITHOUT SECONDARY GENERALIZATION: PHARMACOECONOMIC ANALYSIS FOR THE RUSSIAN FEDERATION HEALTH CARE SYSTEM Abstract  similar documents
N. K. Mazina, I. V. Sheshunov, P. V. Мazin, Yu. V. Kislitsin, E. M. Markova
"... in therapy of primary generalized tonic-clonic seizures (PGTCS). Objective. To determine the effectiveness ..."
 
Vol 12, No 3 (2019) Availability and Pharmacoeconomics of Insulin Therapy in Countries with the Largest Number of Diabetics Abstract  PDF (Eng)  similar documents
S. V. Ponomarenko
"... segmentation, and the costs for insulin replacement therapy in countries with the largest number of patients ..."
 
Vol 5, No 1 (2012) COST OF ILLNESS ANALYSIS: TYPES, METHODOLOGY, RUSSIAN SPECIFICS Abstract  similar documents
R. I. Yagudina, I. Yu. Zinchuk, M. M. Litvinenko
"... of therapy. Cost of illness analysis is a useful tool for effective planning of distribution of economical ..."
 
Vol 9, No 4 (2016) THE COSTS OF REGIONAL ANESTHESIA WITH THE USE OF LEVOBUPIVACAINE, RACEMIC BUPIVACAINE AND ROPIVACAINE Abstract  similar documents
G. E. Ulrikh, A. V. Rudakova
"... levo isomer ropivacaine. The aim of this work was to assess the cost of anesthesia levobupivacaine ..."
 
Vol 8, No 4 (2015) PHARMACOECONOMIC EVALUATION OF INFLUENZA AND PNEUMOCOCCAL VACCINATION IN EMPLOYEES OF THE JOINT STOCK COMPANY "RUSSIAN RAILWAYS" (JSCO "RZD") ON INVESTMENT FOR THE EMPLOYER Abstract  similar documents
D. A. Zhukov
"... statistical software was not used). The author presented the method of direct and indirect costs calculation ..."
 
Vol 12, No 3 (2019) Comorbidity in elderly patients with atrial fibrillation affects the “cost of illness” Abstract  similar documents
S. V. Malchikova , N. S. Maksimchuk-Kolobova, M. V. Kazakovtseva 
"... Objective: to analyze whether comorbidity affects the cost of treatment and medical services ..."
 
Vol 7, No 3 (2014) THE ANALYSIS OF METHODOLOGIC CHARACTERISTICS OF RESEARCHES ON SOCIAL AND ECONOMIC BURDEN OF DISEASES IN RUSSIA IN THE FRAMES OF DEVELOPMENT OF STANDARD COST OF ILLNESS METHODOLOGY FOR THE HEALTH TECHNOLOGY ASSESSMENT Abstract  similar documents
V. I. Ignatyeva, M. V. Avxentyeva
"... there are no uninamioulsly accepted methods and approaches for this type of research. The cost of illness method (assessment ..."
 
Vol 8, No 2 (2015) PHARMACOECONOMIC STUDIES TREATMENT OF PATIENTS WITH INJURIES IN THE DEPARTMENT OF ANESTHESIOLOGY AND RESUSCITATION WITH METHODS ANALYSIS THE COST OF ILLNESS Abstract  similar documents
Anton Alexandrovich Kasatkin
"... of analysis of the cost of the disease, including the payment of medical costs for medical services, medicines ..."
 
Vol 13, No 4 (2020) The social-economic burden of spinal muscular atrophy in Russia Abstract  similar documents
A. S. Kolbin, D. V. Vlodavets, A. A. Kurylev, Yu. Ye. Balykina, M. A. Proskurin, S. A. Mishinova, O. Yu. Germanenko, N. Yu. Kolbina
"... for direct medical procedures and indirect costs before the introduction of pathogenetic therapy and after ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER Abstract  similar documents
A. U. Kulikov
"... of erlotinib as the 2nd line therapy of patients with local or metastatic NSCLC is more preferable than ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis Abstract  similar documents
R. I. Yagudina, M. M. Murashko
"... therapy for patients, suffering from peritonitis disease. Reamberin, Ringer's solution, Plasma-Lyte ..."
 
Vol 12, No 1 (2019) Individual cost accounting in the management of medical organizations Abstract  similar documents
I. A. Zheleznyakova, L. A. Kovaleva, T. A. Khelisupali
"... In the modern economic conditions, the rational planning of costs and the complex process ..."
 
Vol 5, No 1 (2012) PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION Abstract  similar documents
R. Yagudina, A. Kulikov, B. Misikova
"... in the treatment of multiple myeloma in second-line therapy and is preferable from the perspective of the health ..."
 
Vol 6, No 2 (2013) FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS Abstract  similar documents
A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure
"... of type 2 DM therapies liraglutide (Victoza®) was considered as the cost-effective strategy with ICER/QALY ..."
 
Vol 5, No 2 (2012) METHODOLOGY OF COST-UTILITY ANALYSIS IN PHARMACOECONOMICSTUDIES Abstract  similar documents
R. I. Yagudina, I. V. Sorokovikov
"... pharmacoeconomic cost-utility analysis – CUA is at third place by popularity (10% of studies ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC EVALUATION OF TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS ON DIALYSIS WITH CINACALCET Abstract  similar documents
R. I. Yagudina, V. G. Serpik
"... was 20,709 rubles. (Taking into account the costs of dialysis treatments), and for standard therapy - 110 ..."
 
Vol 7, No 1 (2014) ECONOMIC ASSESSMENT OF MAGNESIUM DEFICIENCY CORRECTION FOR BASIC THERAPY EFFICACY OF UNCONTROLLED ASTHMA IN CHILDREN Abstract  similar documents
V. I. Petrov, I. N. Shishimorov, O. V. Magnitskaya, Ju. V. Ponomareva
"... the cost of achieving control and cost per symptom-free day after 12 and 24 weeks of therapy ..."
 
Vol 7, No 2 (2014) THE ANALYSIS OF THE LIPETSK PHARMACEUTICAL MARKET OF NASAL GLUCOCORTICOSTEROID Abstract  similar documents
K. V. Danilova, I. M. Razdorskaya
 
Vol 7, No 2 (2014) THE ANALYSIS OF THE EFFECTIVENESS OF THROMBOPROPHYLAXIS AMONG PREGNANT WOMEN WITH MESENCHYMAL DYSPLASIA Abstract  similar documents
E. G. Kudinova, A. P. Momot, N. V. Trukhacheva
"... and accordingly the economic costs of medical care. ..."
 
Vol 7, No 3 (2014) ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION Abstract  similar documents
M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva
"... -weighted costs of their drug therapy. Data on registered patients with OD was obtained because ..."
 
Vol 8, No 2 (2015) REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS Abstract  similar documents
Andrey Vladislavovich Pavlysh, Aleksei Sergeevich Kolbin, Roman Andreevich Gapeshin, Stanislav Mikhailovich Malyshev
"... need a specific approach due to high costs of the drugs and limited sample size. Cost-utility analysis ..."
 
Vol 8, No 2 (2015) CLINICAL EFFICIENCY AND THE PHARMACOECONOMIC ANALYSIS OF ALLERGEN IMMUNOTHERAPY AT PATIENTS WITH MILD AND MODERATE ALLERGIC BRONCHIAL ASTHMA Abstract  similar documents
Elena Albertovna Sobko, Natalya Vladimirovna Gordeeva, Angelina Yurievna Kraposhina, Irina Anatolyevna Soloveva, Svetlana Vladimirovna Chubarova, Olga Petrovna Ishenko, Irina Vladimirovna Demko, Maria Michailovna Loktionova
"... divided into 4 groups depending on their therapy. The period of observation was 12 months. The 1st group ..."
 
Vol 8, No 2 (2015) REVIEW OF THE INTERNATIONAL PRACTICE OF COST-SHARING MECHANISM IN NATIONAL HEALTH CARE SYSTEMS Abstract  similar documents
Natalia Nikolayevna Sisigina, Vitalii Vladimirovich Omel'yanovskii, Nikolay Alexandrovich Avxentyev
"... The article gives a review of international experience of using of cost-sharing mechanism ..."
 
Vol 9, No 3 (2016) METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREATMENT OF ACYTR OBSTRUCTIVE BRONCHITIS IN CHILDREN IN HOSPITAL Abstract  similar documents
O. V. Zhukova, S. V. Kononova
"... » analysis was used for comparing of the costs and effectiveness for courses of antibiotics, used in therapy ..."
 
Vol 9, No 4 (2016) FACTORS AND EFFECTS OF PRIVATE HEALTH SPENDING Abstract  similar documents
O. A. Zarubina, N. N. Sisigina
"... health expenditure, regulatory measures on cost sharing, paid medical services, voluntary health ..."
 
Vol 10, No 2 (2017) ECONOMIC ASSESSMENT OF THE EFFECTIVENESS AND SAFETY OF THE COMMONLY PRACTICED PERIOPERATIVE ANTIBIOTIC PROPHYLAXIS (BASED ON AN EARLIER EPIDEMIOLOGICAL SURVEY OF MULTIDISCIPLINARY HOSPITALS) Abstract  similar documents
Yu. M. Gomon, A. S. Kolbin, S. V. Sidorenko, A. M. Kuzhel’, A. V. Repina, Yu. V. Lobzin, Yu. E. Balykina
"... approved for national clinical practice. Aim. To perform a cost-effectiveness analysis of the commonly ..."
 
Vol 10, No 4 (2017) PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... -replacement of joints. According to the "cost-effectiveness" analysis, the best-fit therapy regimen ..."
 
Vol 12, No 2 (2019) Comparative modeling of socio-economic burden among smokers, nonsmokers and former smokers Abstract  similar documents
E. V. Radchenko, A. S. Kolbin
"... , the burden of tobacco smoking (including the direct costs of medical care and payment for temporary ..."
 
Vol 12, No 4 (2019) Comparative clinical and economic analysis of using SYSADOA drugs containing chondroitin sulphate or influencing its biosynthesis in the treatment of patients with stage II knee osteoarthritis Abstract  similar documents
I. V. Sarvilina, A. N. Galustyan, A. K. Hadzhidis, I. S. Sardaryan, N. V. Lavrov, O. A. Gromova, Yu. S. Prokofieva
"... & Lawrence classification. We calculated the cost-effectiveness from the direct costs and treatment ..."
 
Vol 12, No 4 (2019) Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation Abstract  similar documents
S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev
"... . The cost-effectiveness ratios for omalizumab, mepolizumab and reslizumab were calculated and compared ..."
 
Vol 12, No 4 (2019) Optimization of drug supply for patients with malignant neoplasms in a region of the Russian Federation Abstract  similar documents
A. V. Nikitina, F. V. Gorkavenko, Y. S. Saybel, M. V. Avxentyeva, M. S. Sura, D. V. Fedyaev
"... The aim was to assess the possibility of optimizing the costs of drugs for cancer patients ..."
 
Vol 12, No 4 (2019) Crucial areas of the economic analysis of public cancer care Abstract  similar documents
D. A. Andreev, K. I. Polyakova, A. A. Zavyalov, T. N. Ermolaeva, A. G. Fisun, A. D. Ermolaeva, V. A. Dubovtseva, T. E. Maksimova
"... cancer care for Moscow residents. The aim of this study was to identify the crucial areas of the cost ..."
 
Vol 14, No 2 (2021) Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis Abstract  similar documents
A. V. Rudakova, D. G. Tolkacheva, V. D. Sokolova
"... impact analysis showed that the inclusion of netakimab in the therapy for PsA could reduce the costs ..."
 
Vol 14, No 2 (2021) Organizational and economic aspects of triplet therapy of relapsed/refractory multiple myeloma in the Russian healthcare setting Abstract  similar documents
E. A. Pyadushkina, E. V. Derkach, V. I. Ignatyeva, E. E. Yagnenkova, T. Yu. Klitochenko, T. V. Shelekhova, A. N. Levanov
"... the cost of targeted therapy was estimated. Results. The cost of an annual course of triplet therapy per ..."
 
Online First Health-economic evaluation of risdiplam (Evrysdi®) in patients with spinal muscular atrophy Abstract  similar documents
А. S. Kolbin, А. А. Kurylev, Yu. Е. Balykina, М. А. Proskurin, S. А. Mishinova
"... . Cost-minimization analysis was used. We accounted for direct medical costs of pathogenic treatment ..."
 
Vol 13, No 4 (2020) Evaluation of the economic effect of biological therapy in patients with severe COVID-19 and cytokine storm Abstract  similar documents
M. Yu. Frolov, A. S. Salasyuk, V. A. Rogov
"... by reducing the cost of drug therapy will be 1,251,698.99 rubles per 72 patients when comparing olokizumab ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH FIX COMBINATION OF CARBONIC ANHYDRASE INHIBITORS AND BETABLOCKERS Abstract  similar documents
M. V. Protsenko
"... of carbonic anhydrise inhibitors and betablockers by mean of cost-utility, willingness-to-pay, cost ..."
 
Vol 9, No 1 (2016) COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN Abstract  similar documents
V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva
"... therapy is the preferred alternative to basal insulins, due to lower costs and improvement in the quality ..."
 
Vol 11, No 4 (2018) Clinical and economic studies on pharmacotherapy of malignant neoplasms: the modeling approach Abstract  similar documents
A. G. Tolkushin, S. K. Zyryanov, N. L. Pogudina, M. V. Davydovskaya
"... therapy and with adverse events (Ae), as well the costs associated with disease progression (for certain ..."
 
Vol 6, No 2 (2013) COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... performed cost-effectiveness analysis on the basis of two tyrosine kinase inhibitors in Russian Federation ..."
 
Vol 5, No 2 (2012) WORKING OUT OF STRATEGY OF STOREKEEPING OF PHARMACEUTICAL FIRM Abstract  similar documents
A. I. Borodin
 
Vol 10, No 2 (2017) COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD Abstract  similar documents
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov
"... ) was used as the main criterion of effectiveness. Direct medical costs of drug therapy, and the costs ..."
 
1 - 50 of 99 Items 1 2 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)